NSE: EMCURE · 4 November 2026
- Emcure Pharmaceuticals has risen 15.43% over 2 trading sessions; today's move is +9.30%.
- Emcure Pharmaceuticals submitted its unaudited financial results for the quarter ended September 30, 2026, reporting operating revenue of ₹28,205 million, a 24.3% year-on-year increase. Profit after tax rose 29.3% year-on-year to ₹3,251 million, driven by solid traction across domestic and international markets. EBITDA grew by 30.9% to ₹5,748 million with margins expanding by 103 basis points to 20.4%.
- Trading volume was 8.09 times the 20-day average daily volume.
Emcure Pharmaceuticals share price: 15.43% rise over 2 trading sessions
Emcure Pharmaceuticals Ltd. (EMCURE) shares moved sharply higher today, surging 9.30% to close at ₹2,160.40. The stock traded within a daily range of ₹2,035.10 and ₹2,174.20, after opening at ₹2,110.10 compared to its previous close of ₹1,976.60.
The broader market and sector indices showed positive momentum, with the benchmark Nifty rising 0.63% and the Nifty Pharma sector gaining 0.42%. Emcure's robust double-digit advance significantly outperformed both the broader market and its sector peers, building on strong near-term momentum that includes a 5-day return of 15.96% and a 20-day return of 13.10%.
The price move follows the company's recent Q2FY27 financial results release on November 3, 2026, which reported operating revenue growth of 24.30% year-on-year to ₹28,205 million and a 29.30% jump in profit after tax to ₹3,251 million. Management also highlighted strong domestic and international business performance alongside ongoing portfolio expansion across key therapeutic segments, which appears to have strongly supported investor sentiment.
11.90 lakh shares traded by 4 November 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 1.47 lakh shares (8.09 times). The five-day average daily volume was 2.60 lakh shares. Separately, the NSE report for 4 November 2026 showed 4.40 lakh shares delivered, representing 36.98% of that day’s traded volume. The same report recorded 59,392 trades.
The stock's 9.30% rally on volumes exceeding 8 times its 20-day average directly follows the company's release of robust Q2FY27 financial results showing a 29.30% rise in net profit and 24.30% revenue growth.
Latest Company Developments
Emcure Pharmaceuticals submitted its unaudited financial results for the quarter ended September 30, 2026, reporting operating revenue of ₹28,205 million, a 24.3% year-on-year increase. Profit after tax rose 29.3% year-on-year to ₹3,251 million, driven by solid traction across domestic and international markets. EBITDA grew by 30.9% to ₹5,748 million with margins expanding by 103 basis points to 20.4%.
Strong quarterly earnings and margin expansion directly validate the company's growth trajectory and operational efficiency.
The board of directors approved a proposed scheme of amalgamation for wholly owned subsidiaries Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited with the holding company, Emcure Pharmaceuticals Limited. The restructuring is subject to requisite statutory and regulatory approvals. It forms part of the 'One Emcure' vision to simplify the group holding structure.
Simplifying the group structure aims to achieve operational synergies and streamline backend and corporate functions.
The company disclosed the receipt of various orders from the Income-tax Department imposing an aggregate penalty of ₹57,73,96,732 for financial years 2014-15 to 2020-21. Emcure stated that it is evaluating appropriate legal remedies, including filing appeals before the appropriate Appellate Authority.
Discloses potential tax liabilities and ongoing litigation items that the company is actively contesting.
Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 7.05% on 30 September 2026. This compares with 6.87% on 30 June 2026, a change of +0.18 percentage points.
The filing reported 23 MF/UTI holders.
Research & Brokerage Views
Analyst Osho Krishan highlighted Emcure shares as a technical buy recommendation alongside other key market stocks.
Historical Bulk / Block Deals
What to Watch Next
- Execution and regulatory approvals regarding the proposed amalgamation of Zuventus Healthcare and Emcutix Biopharmaceuticals.
- Sustained delivery and volume participation relative to the 20-day average volume of 8.09x seen today.
- Progress on international market pipelines including Canada and RoW non-ARV product approvals.
- Updates regarding legal remedies pursued against the Income-tax Department penalty orders.
Other Dated Coverage
More Emcure Pharmaceuticals news and dated analysis →
Frequently Asked Questions
What is the latest Emcure Pharmaceuticals company news?
Emcure Pharmaceuticals submitted its unaudited financial results for the quarter ended September 30, 2026, reporting operating revenue of ₹28,205 million, a 24.3% year-on-year increase. Profit after tax rose 29.3% year-on-year to ₹3,251 million, driven by solid traction across domestic and international markets. EBITDA grew by 30.9% to ₹5,748 million with margins expanding by 103 basis points to 20.4%.
How strong was Emcure Pharmaceuticals’s trading volume?
11.90 lakh shares traded, 8.09 times the 20-day average daily volume. The price and volume data are dated 4 November 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.